Company news

Mirum Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

January 3, 2022

Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index

December 14, 2021

LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at NASPGHAN Annual Meeting 2021

December 12, 2021

Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting

December 5, 2021

Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher

November 16, 2021

Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome

November 14, 2021

Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

November 14, 2021

Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021

November 7, 2021

The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome

October 31, 2021

New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021

October 31, 2021

U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older

September 28, 2021

Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

September 20, 2021

Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison

September 12, 2021

Mirum Pharmaceuticals to Participate in September Investor Conferences

September 1, 2021

Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors

August 18, 2021

Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

August 4, 2021

Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea

July 25, 2021

Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors

June 6, 2021

Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

May 5, 2021

Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021

April 28, 2021

Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome

April 25, 2021

Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis

April 11, 2021

Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille Syndrome

March 28, 2021

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates

March 8, 2021

Mirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in Alagille Syndrome

January 31, 2021

Mirum Pharmaceuticals Honors Alagille Syndrome Awareness Day with Launch of Disease Awareness Campaign

January 23, 2021

Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing Cholangitis

January 13, 2021

Mirum Pharmaceuticals Provides Corporate Update

January 11, 2021

Mirum Pharmaceuticals Announces Virtual Investor Day 2020

December 6, 2020

Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2

November 29, 2020

Mirum Pharmaceuticals Announces Data Presented During AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with Alagille Syndrome Treated with Maralixibat

November 14, 2020

Mirum Pharmaceuticals Provides Third Quarter 2020 Financial Results and Business Update, and Announces Virtual Investor Day

November 11, 2020

Mirum Pharmaceuticals Broadens Expanded Access Program for Maralixibat in Alagille Syndrome to Europe and Australia

November 4, 2020

Mirum Pharmaceuticals Announces New Data Being Presented in Late-Breaker Oral and Poster Presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

November 1, 2020

Mirum Pharmaceuticals Announces Partnership With EVERSANA to Support Launch and Commercialization of Maralixibat for Alagille Syndrome in the United States

October 14, 2020

Mirum Pharmaceuticals Initiates Rolling Submission of a New Drug Application for Maralixibat for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome and Launches Expanded Access Program

August 31, 2020

Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival Data for Patients With PFIC2 at Digital International Liver Congress 2020

August 28, 2020

Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates

August 5, 2020

Mirum’s Maralixibat Demonstrates Transplant-Free Survival for Pediatric Patients with Progressive Familial Intrahepatic Cholestasis

June 1, 2020

Mirum Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Updates

May 6, 2020

Mirum Pharmaceuticals Appoints Peter Radovich as Chief Operating Officer

April 27, 2020

Mirum Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

March 11, 2020

Mirum Pharmaceuticals Promotes Ian Clements to Chief Financial Officer

January 13, 2020

Mirum Pharmaceuticals Announces Pricing of Public Offering

January 7, 2020

Mirum Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Maralixibat

December 15, 2019

Mirum Pharmaceuticals Presents Data Demonstrating Long-term Durability of Treatment Effect of Maralixibat in Children With Cholestatic Liver Diseases

November 7, 2019

Mirum Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update

November 5, 2019

Mirum Pharmaceuticals Announces Appointment of Ed Tucker as Chief Medical Officer

October 27, 2019

Mirum Pharmaceuticals to Present New Data at The Liver Meeting 2019

September 30, 2019

Mirum Pharmaceuticals Announces Pricing of Initial Public Offering

July 16, 2019

← Newer news releases

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 22 decks. Every deck is listed under its year.